Progress In Neurotherapeutics And Neuropsychopharmacology: Volume 3, 2008

Progress in Neurotherapeuticsand Neuropsychopharmacology 2008 Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidencebased practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurological and psychiatric illnesses, and non-drug treatments. Each article is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an Editor-in-Chief and Editorial Board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurological and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. Articles also available at http://www.cambridge. org/jid_PNN Editor-in-Chief Jeffrey L. Cummings, MD Department of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Editorial Board Peter Goadsby,MD, PhD Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK Karl Kieburtz, MD, FAAN Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA Joseph Masdeu, MD, PhD, FAAN Department of Neurology, University of Navarre Medical School Pamplona, Spain GaryTollefson,MD,PhD Orexigen Therapeutics, Inc. and Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA Progress in Neurotherapeutics and Neuropsychopharmacology 2008 VOL. 3(1) 2008 Editor-in-Chief Jeffrey L. Cummings, MD The Augustus S. Rose Professor of Neurology Professor of Psychiatry and Biobehavioral Sciences Director, Mary S. Easton Center for Alzheimer's Disease Research Director, Deane F. Johnson Center for Neurotherapeutics David Geffen School of Medicine at UCLA CAMBRIDGE UNIVERSITY PRESS CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo, Delhi Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK Published in the United States of America by Cambridge University Press, New York www. Cambridge. org Information on this title: www.cambridge.org/9780521115612 © Cambridge University Press 2008 This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Pres